Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) has issued an announcement.
Charmacy Pharmaceutical Co., Ltd. has announced that its Board of Directors will convene on August 28, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the potential payment of an interim dividend. This announcement signals the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and investor relations.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a joint stock limited liability company incorporated in the People’s Republic of China. The company operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products.
Average Trading Volume: 54,526
Technical Sentiment Signal: Sell
Current Market Cap: HK$646.9M
See more insights into 2289 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money